Publication | Open Access

Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

OncologyMalignant DiseaseRandomized StudyBrief ReportPathologyPleural DiseaseCancer TreatmentPhase 2MedicineRadiation OncologyCancer Research